AstraZeneca's BREZTRI wins US approval for asthma treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
April 28, 2026 7:00 AM EDTApproval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZenecas single-inhaler fixed-dose triple therapy compared with inhaled dual therapy
Approval is second indication for BREZTRI beyond COPD
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZenecas fixed-dose triple-combination therapy BREZTRI Aerosphere® (budesonide/glycopyrrolate/formoterol fumarate or BGF 320/36/9.6g) has been approved in the US for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older. BREZTRI is a single-inhaler that combines the efficacy of corticosteroid/long-acting... More
